ES2149750T1 - Compuestos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas a base de tales compuestos. - Google Patents

Compuestos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas a base de tales compuestos.

Info

Publication number
ES2149750T1
ES2149750T1 ES99670003T ES99670003T ES2149750T1 ES 2149750 T1 ES2149750 T1 ES 2149750T1 ES 99670003 T ES99670003 T ES 99670003T ES 99670003 T ES99670003 T ES 99670003T ES 2149750 T1 ES2149750 T1 ES 2149750T1
Authority
ES
Spain
Prior art keywords
compounds
cyclodextrins
preparation
salts
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES99670003T
Other languages
English (en)
Other versions
ES2149750T3 (es
Inventor
Cerdeira Ana Maria Mendes
Sousa Goucha Jorge Pedro Ma De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tecnimede Sociedade Tecnico Medicinal SA
Original Assignee
Tecnimede Sociedade Tecnico Medicinal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal SA filed Critical Tecnimede Sociedade Tecnico Medicinal SA
Publication of ES2149750T1 publication Critical patent/ES2149750T1/es
Application granted granted Critical
Publication of ES2149750T3 publication Critical patent/ES2149750T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Complejo de inclusión estable de una sal de aminoácido de un derivado de bencimidazol y de una ciclodextrina, obtenible mediante el procedimiento que comprende las etapas de: a. disolver el aminoácido en agua o en una mezcla de etanol:agua; b. añadir el derivado de bencimidazol a esta solución; c. mezclar la solución a elevada velocidad durante 1 a 10 minutos; d. añadir una ciclodextrina a la solución obtenida en la etapa C mientras se mantiene una fuerte agitación durante 0, 5 a 24 horas; e. preparar el complejo de inclusión estable final mediante un método seleccionado entre secado por aspersión, liofilización, evaporación del disolvente bajo presión reducida, por deposición sobre núcleos inertes o por un proceso de granulación, para obtener comprimidos o pellets mediante extrusión-esferonización.
ES99670003T 1999-01-06 1999-01-06 Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos. Expired - Lifetime ES2149750T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99670003A EP1018340B1 (en) 1999-01-06 1999-01-06 Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them

Publications (2)

Publication Number Publication Date
ES2149750T1 true ES2149750T1 (es) 2000-11-16
ES2149750T3 ES2149750T3 (es) 2004-06-01

Family

ID=8242616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99670003T Expired - Lifetime ES2149750T3 (es) 1999-01-06 1999-01-06 Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos.

Country Status (5)

Country Link
EP (1) EP1018340B1 (es)
AT (1) ATE249218T1 (es)
DE (1) DE69911159T2 (es)
ES (1) ES2149750T3 (es)
PT (1) PT1018340E (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
JP2005514443A (ja) * 2002-01-15 2005-05-19 アルタナ　ファルマ　アクチエンゲゼルシャフト パントプラゾール・シクロデキストリン包接錯体
PT2260871E (pt) 2004-04-01 2013-08-01 Pf Medicament Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente para interação com o complexo
RU2411043C2 (ru) 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
CN1813729A (zh) * 2005-02-02 2006-08-09 兰贝克赛实验室有限公司 苯并咪唑化合物的注射制剂
EP1801110A1 (en) * 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
ES2294931B1 (es) * 2006-06-29 2008-12-16 Quimica Sintetica, S.A. Sal de l-arginina de esomeprazol, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
EA200900985A1 (ru) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
WO2009144220A1 (en) * 2008-05-29 2009-12-03 Universite Libre De Bruxelles Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
CN104546842B (zh) * 2014-12-24 2017-08-04 辰欣药业股份有限公司 一种奥美拉唑组合物及其制备方法
US10786458B2 (en) * 2015-03-31 2020-09-29 Laboratorios Bago S.A. Procedure for preparing enteric-coated pellets containing a proton pump inhibitor and multi-particle pharmaceutical compositions containing them
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN113461836B (zh) * 2021-06-16 2022-06-03 华南农业大学 氨基酸环糊精衍生物作为农药增效剂的应用
WO2025078989A1 (en) 2023-10-11 2025-04-17 Reena Patel Stabilized pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
WO1998040069A2 (en) * 1997-03-13 1998-09-17 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations

Also Published As

Publication number Publication date
EP1018340A9 (en) 2001-04-04
ATE249218T1 (de) 2003-09-15
PT1018340E (pt) 2003-12-31
EP1018340B1 (en) 2003-09-10
ES2149750T3 (es) 2004-06-01
EP1018340A1 (en) 2000-07-12
DE69911159T2 (de) 2004-06-24
DE69911159D1 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
ES2149750T1 (es) Compuestos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas a base de tales compuestos.
IS1854B (is) Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.
DK0830377T4 (da) Glucagon-lignende peptid-2 og terapeutisk anvendelse deraf
NO20023313L (no) Nye substituerte benzimidazol doseringsformer og fremgangsmåte for anvendelse av samme
BR9506029A (pt) Forma farmaêutica oral de múltipla dosagem unitária em tablete processo para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem para o tratamento de doenças inflamatórias gastrointestinais em maniferos e no homem e embalgem de ampola de pressão transversal
SE9702483D0 (sv) New compound
FI96274C (fi) Menetelmä valmistaa pimobendaanin oraalisia lääkeainemuotoja
DE69833157D1 (de) Stabile orale pharmazeutische Zusammensetzung enthaltend ein Pyridylsulfinyl-substituiertes Benzimidazole
ES2675581T3 (es) Método para producir gránulos de un compuesto de bencimidazol recubiertos
KR20080080408A (ko) 방출 제어 고형 제제
ATE247960T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
HRP20040596A2 (en) Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound
DK0544760T3 (da) Farmaceutiske præparater indeholdende 5-difluormethoxy-2- (3,4-dimethoxy-2-pyridyl)methylsulfinyl benzimidazol og at anti-helicobactermiddel til behandling af gastrointestinale lidelser
NO892512L (no) Oralt preparat av buspiron og salter derav.
ES2232459T3 (es) Derivados de benzimidazol antiulcerosos estables frente a los acidos de administracion oral.
JP2005154431A (ja) 固形製剤
JP4331930B2 (ja) 酸に不安定な薬物の高含量顆粒
JP2005523298A (ja) 非心臓性胸痛の治療のためのプロトンポンプ阻害剤の使用
JP2005522462A (ja) 気道疾患の治療のためのプロトンポンプ阻害剤の使用
DE60040856D1 (de) Lactalbumin zur kurativen Behandlung von Magengeschwüren
Petryszyn et al. Pharmacodynamics, pharmacokinetics, drug interactions, toxicity and clinical efficacy of proton pump inhibitors–are the differences significant?
RU93058142A (ru) Производные хинолина, способ их получения, фармацевтическая композиция и способ лечения